Antibody Status | From 6 months | ||||||||
---|---|---|---|---|---|---|---|---|---|
Abatacept | Other bDMARD | Incremental difference | |||||||
Cohort (n) | Mean | 95% CI | Cohort (n) | Mean | 95% CI | LS Mean | 95% CI | P value | |
DAS28-ESR | |||||||||
 All patients | 92 | −1.59 | −1.95,-1.23 | 145 | −1.56 | − 1.87,-1.24 | − 0.04 | − 0.45,0.38 | 0.86 |
 ACPA+ | 48 | −1.58 | −2.09,-1.06 | 60 | − 1.21 | −1.71,-0.71 | −0.37 | − 0.97,0.24 | 0.24 |
 ACPA- | 20 | −2.03 | −2.96,-1.09 | 30 | −1.92 | −2.79,-1.05 | − 0.11 | − 0.94,0.73 | 0.81 |
 RF+ | 65 | −1.57 | −2.00,-1.15 | 94 | −1.39 | − 1.78,-1.00 | −0.19 | −0.69,0.32 | 0.47 |
 RF- | 21 | −1.73 | −2.59,-0.86 | 34 | −2.01 | − 2.83,-1.18 | 0.28 | −0.51,1.08 | 0.49 |
 ACPA+/RF+ | 45 | −1.58 | −2.10,-1.05 | 47 | − 1.10 | − 1.61,-0.59 | −0.48 | − 1.11,0.15 | 0.14 |
 ACPA+/RF- | a | −2.59 | −36.06,30.88 | a | −2.35 | − 54.75,50.05 | −0.24 | −5.27,4.79 | 0.93 |
 ACPA−/RF+ | a | −2.55 | −4.73,-0.37 | 6 | −1.28 | −3.22,0.66 | − 1.27 | − 3.14,0.60 | 0.22 |
 ACPA−/RF- | 16 | −1.88 | −2.82,-0.93 | 24 | −2.02 | −2.91,-1.12 | 0.14 | −0.76,1.04 | 0.76 |
DAS28-CRP | |||||||||
 All patients | 116 | −1.55 | − 1.82,-1.28 | 106 | −1.39 | − 1.68,-1.09 | −0.16 | − 0.50,0.18 | 0.36 |
 ACPA+ | 48 | −1.49 | − 1.94,-1.05 | 42 | −1.20 | − 1.71,-0.69 | −0.29 | − 0.83,0.24 | 0.28 |
 ACPA- | 11 | −1.28 | −2.22,-0.35 | 21 | −1.14 | −1.88,-0.40 | −0.14 | − 1.22,0.93 | 0.80 |
 RF+ | 87 | −1.66 | −1.97,-1.35 | 69 | −1.43 | − 1.80,-1.06 | − 0.23 | − 0.64,0.18 | 0.27 |
 RF- | 17 | −1.25 | −2.04,-0.47 | 25 | −1.48 | −2.21,-0.76 | 0.23 | −0.67,1.13 | 0.62 |
 ACPA+/RF+ | 44 | −1.50 | −1.94,-1.06 | 38 | −1.04 | − 1.55,-0.53 | −0.46 | −1.02,0.11 | 0.12 |
 ACPA+/RF- | a | −2.06 | −13.11,9.00 | a | −2.80 | −19.06,13.46 | 0.74 | −2.47,3.96 | 0.69 |
 ACPA−/RF+ | a | −3.10 | −4.32,-1.89 | 6 | −0.88 | −1.97,0.22 | −2.22 | − 3.64,-0.81 | 0.01 |
 ACPA−/RF- | 6 | 0.18 | −1.02,1.38 | 15 | −1.11 | −1.94,-0.29 | 1.30 | −0.08,2.67 | 0.07 |